Abstract 244P
Background
Non clear cell renal cell carcinoma (nccRCC) refers to a rare diverse heterogeneous group of tumors; usually treated with immunotherapy (IO) and or tyrosine kinase inhibitors (TKI). Prospective large-scale data from Asia specific countries is limited. We aimed to present the demographic profile and treatment outcome of nccRCC patients from single centre in India.
Methods
This is a retrospective study on patients with metastatic nccRCC treated at Tata Medical Centre, Kolkata-West Bengal from 2012-2022. Demographic profiles, histologic subtypes, treatment details, response to therapy (by RECIST v1.1) and survival status were captured from electronic medical records of hospitals up till March 2023. Progression free survival (PFS) and Overall survival (OS) were estimated using Kaplan Meier method.
Results
A total of 89 patients were screened;24 excluded due to inadequate records. 65 patients were included in analysis, with a median age at diagnosis of 59 years (range 20-84). Histologic subtypes comprised 43% (n=28) papillary, 31%(n=20) clear cell with mixed histology, 3%(2) sarcomatoid & 23%(15) others including chromophobe, oncocytoma. The most common site of metastasis was lung 62% (n=40).15% presented with haematuria and 62%(n=40) underwent cytoreductive nephrectomy. Majority received pazopanib 46% (n=30) then chemotherapy 20% (n=13) including bevacizumab plus erlotinib, sunitinib 15%(10), cabozantinib 14%(9). Only 3(5%) received IO plus TKI combination. The best response was CR in 1.5%, PR 20%, SD 51% & PD 23% as per RECIST v1.1. Total 17 (26%) patients required dose reduction & interruption due to adverse effects & 33% received second-line therapy with nivolumab,axitinib & everolimus were commonly used. After a median follow up of 44 months; median PFS was 13 months (95%CI 7.2-18.9) & median OS was 17 months (95%CI 12.1-22.1). Regression analysis identified better outcome for PFS & OS with sarcomatoid subtype & those underwent prior nephrectomy.
Conclusions
The overall response and survival was quite impressive in comparison with published data; despite limited number of cases treated with IO due to its cost.This study also highlighted better survival with sarcomatoid subtype and prior nephrectomy.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
73TiP - Global phase III studies evaluating vepdegestrant in estrogen receptor (ER)+/human epidermal growth factor receptor 2 (HER2)- advanced breast cancer: VERITAC-2 and VERITAC-3
Presenter: Hiroji Iwata
Session: Poster Display
Resources:
Abstract
78P - First-in-human phase I study of TT-00434, an orally available FGFR (1-3) inhibitor in patients with advanced solid tumors
Presenter: Chia Jui Yen
Session: Poster Display
Resources:
Abstract
79P - Accelerated identification of recurrent neoantigens for the development of off-the-shelf cancer vaccines
Presenter: Le Son Tran
Session: Poster Display
Resources:
Abstract
80P - Safety, preliminary efficacy, and pharmacokinetics of HLX26 plus serplulimab in advanced solid tumours: An open-label, dose-escalation phase I study
Presenter: Yanmin Wu
Session: Poster Display
Resources:
Abstract
81P - A first-in-human, multiple dose and dose escalation phase I study to investigate the safety, tolerability and antitumor activity of SmarT cells plus PD-1 blocking antibodies in patients with far advanced/metastatic solid tumors
Presenter: Qin Liu
Session: Poster Display
Resources:
Abstract
82P - NEXUS: A phase I dose escalation study of selinexor plus nivolumab and ipilimumab in Asian patients with advanced/metastatic solid malignancies
Presenter: Gloria Chan
Session: Poster Display
Resources:
Abstract
83P - The updated report of phase I trial of VG2025, a non-attenuated HSV-1 oncolytic virus expressing IL-12 and IL-15/RA payloads, in patients with advanced solid tumors
Presenter: Yinan Shen
Session: Poster Display
Resources:
Abstract
84P - T cell receptor repertoire profiles of tumor -infiltrating lymphocytes improves neoantigen prioritization for personalized cancer immunotherapy
Presenter: Tran Nguyen
Session: Poster Display
Resources:
Abstract
85P - Oligometastatic solid tumors: Disease characteristics and role of local therapies
Presenter: Alshimaa Al Hanafy
Session: Poster Display
Resources:
Abstract
86P - Efficacy and safety of HLX07 monotherapy in advanced cutaneous squamous cell carcinoma: An open-label, multicentre phase II study
Presenter: Changxing Li
Session: Poster Display
Resources:
Abstract